ClinicalTrials.gg
CompletedNCT01540487Updated Aug 6, 2013Results posted

Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin

A Phase 1 interventional study of linagliptin/metformin(high dose) and Linagliptin/metformin(low dose) in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-06.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The aim of the trial is to assess the relative bioavailability of fixed dose combination tablets of linagliptin and metformin compared to the administration of two single tablets (linagliptin and metformin ) in Chinese subjects. The availability of a fixed dose combination tablet is expected to significantly enhance patients' compliance with antidiabetic treatment., in particular with concern to the frequent polypharmacy in diabetic patients.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects

Exclusion criteria

Exclusion criteria:

  1. Any relevant deviation from healthy conditions
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    linagliptin/metformin(high dose)

    24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (high dose) tablets single dose in randomized order

    Drug: linagliptin/metformin(high dose)

  • Experimental
    linagliptin/metformin(low dose)

    24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (low dose) tablets single dose in randomized order

    Drug: Linagliptin/metformin(low dose)

Interventions

  • Druglinagliptin/metformin(high dose)

    Drug pages: Linagliptin · Metformin

    patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (High dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.

  • DrugLinagliptin/metformin(low dose)

    Drug pages: Linagliptin · Metformin

    patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (Low dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72)

    Time frame: 1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.

  2. Maximum Measured Concentration (Cmax) of Linagliptin.

    Time frame: 1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.

  3. Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval 0 to the Last Quantifiable Concentration (AUC0-tz)

    Time frame: 1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.

  4. Maximum Measured Concentration (Cmax) of Metformin

    Time frame: 1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.

Secondary outcomes

  1. Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity) for Linagliptin

    AUC0-infinity is based on predicted last concentration values.

    Time frame: 1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.

  2. AUC(0-infinity) for Metformin

    AUC0-infinity is based on predicted last concentration values.

    Time frame: 1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.

  3. AUC0-tz for Linagliptin

    Time frame: 1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.

07

Results

Posted Aug 6, 2013

Participant flow

Participant flow — Overall Study
MilestoneLina 2.5mg, Metformin 850mgLina 2.5mg, Metformin 500mg
Started2424
Completed2324
Not completed10
Withdrew: Protocol violation10

Outcome measures

PrimaryArea Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72)
Time frame:
1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.
Reported as:
Geometric mean · nmol*h/L
Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72)
nmol*h/LLinagliptin 2.5 mg, Metformin 850 mg as FDC TabletLinagliptin 2.5 mg, Metformin 850 mg as Single TabletsLinagliptin 2.5 mg, Metformin 500 mg as FDC TabletLinagliptin 2.5 mg, Metformin 500 mg as Single Tablets
Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72)248 ± 14.5251 ± 15.3266 ± 22.1264 ± 23.8
Statistical analysis
  • Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet vs Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets · ANOVA · Adjusted gmean ratio: 99.5 · 90% CI 94.7 to 104.5
  • Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet vs Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets · ANOVA · Adjusted gmean ratio: 100.8 · 90% CI 95.1 to 106.8
PrimaryMaximum Measured Concentration (Cmax) of Linagliptin.
Time frame:
1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.
Reported as:
Geometric mean · nmol/L
Maximum Measured Concentration (Cmax) of Linagliptin.
nmol/LLinagliptin 2.5 mg, Metformin 850 mg as FDC TabletLinagliptin 2.5 mg, Metformin 850 mg as Single TabletsLinagliptin 2.5 mg, Metformin 500 mg as FDC TabletLinagliptin 2.5 mg, Metformin 500 mg as Single Tablets
Maximum Measured Concentration (Cmax) of Linagliptin.6.90 ± 23.16.81 ± 18.27.54 ± 35.46.77 ± 25.9
Statistical analysis
  • Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet vs Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets · ANOVA · Adjusted gmean ratio: 101.9 · 90% CI 95.4 to 109.0
  • Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet vs Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets · ANOVA · Adjusted gmean ratio: 111.4 · 90% CI 100.4 to 123.5
PrimaryArea Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval 0 to the Last Quantifiable Concentration (AUC0-tz)
Time frame:
1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval 0 to the Last Quantifiable Concentration (AUC0-tz)
ng*h/mLLinagliptin 2.5 mg, Metformin 850 mg as FDC TabletLinagliptin 2.5 mg, Metformin 850 mg as Single TabletsLinagliptin 2.5 mg, Metformin 500 mg as FDC TabletLinagliptin 2.5 mg, Metformin 500 mg as Single Tablets
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval 0 to the Last Quantifiable Concentration (AUC0-tz)11700 ± 27.912100 ± 23.28240 ± 20.88010 ± 21.3
Statistical analysis
  • Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet vs Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets · ANOVA · Adjusted gmean ratio: 97.0 · 90% CI 90.6 to 103.8
  • Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet vs Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets · ANOVA · Adjusteg gmean ratio: 103.0 · 90% CI 96.2 to 110.1
PrimaryMaximum Measured Concentration (Cmax) of Metformin
Time frame:
1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.
Reported as:
Geometric mean · ng/mL
Maximum Measured Concentration (Cmax) of Metformin
ng/mLLinagliptin 2.5 mg, Metformin 850 mg as FDC TabletLinagliptin 2.5 mg, Metformin 850 mg as Single TabletsLinagliptin 2.5 mg, Metformin 500 mg as FDC TabletLinagliptin 2.5 mg, Metformin 500 mg as Single Tablets
Maximum Measured Concentration (Cmax) of Metformin1680 ± 34.81780 ± 26.01220 ± 29.11190 ± 27.2
Statistical analysis
  • Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet vs Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets · ANOVA · Adjusted gmean ratio: 94.6 · 90% CI 85.4 to 104.8
  • Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet vs Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets · ANOVA · Adjusted gmean ratio: 102.5 · 90% CI 92.2 to 113.9
SecondaryArea Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity) for Linagliptin

AUC0-infinity is based on predicted last concentration values.

Time frame:
1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.
Reported as:
Geometric mean · nmol*h/L
Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity) for Linagliptin
nmol*h/LLinagliptin 2.5 mg, Metformin 850 mg as FDC TabletLinagliptin 2.5 mg, Metformin 850 mg as Single TabletsLinagliptin 2.5 mg, Metformin 500 mg as FDC TabletLinagliptin 2.5 mg, Metformin 500 mg as Single Tablets
Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity) for Linagliptin471 ± 29.8433 ± 22.2483 ± 32.5541 ± 36.4
Statistical analysis
  • Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet vs Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets · ANOVA · Adjusted gmean ratio: 110.1 · 90% CI 100.5 to 120.6
  • Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet vs Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets · ANOVA · Adjusted gmean ratio: 89.3 · 90% CI 80.2 to 99.3
SecondaryAUC(0-infinity) for Metformin

AUC0-infinity is based on predicted last concentration values.

Time frame:
1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.
Reported as:
Geometric mean · ng*h/mL
AUC(0-infinity) for Metformin
ng*h/mLLinagliptin 2.5 mg, Metformin 850 mg as FDC TabletLinagliptin 2.5 mg, Metformin 850 mg as Single TabletsLinagliptin 2.5 mg, Metformin 500 mg as FDC TabletLinagliptin 2.5 mg, Metformin 500 mg as Single Tablets
AUC(0-infinity) for Metformin12200 ± 25.812500 ± 23.08440 ± 19.38210 ± 20.3
Statistical analysis
  • Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet vs Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets · ANOVA · Adjusted gmean ratio: 98.0 · 90% CI 92.0 to 104.5
  • Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet vs Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets · ANOVA · Adjusted gmean ratio: 102.8 · 90% CI 97.0 to 109.0
SecondaryAUC0-tz for Linagliptin
Time frame:
1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.
Reported as:
Geometric mean · nmol*h/L
AUC0-tz for Linagliptin
nmol*h/LLinagliptin 2.5 mg, Metformin 850 mg as FDC TabletLinagliptin 2.5 mg, Metformin 850 mg as Single TabletsLinagliptin 2.5 mg, Metformin 500 mg as FDC TabletLinagliptin 2.5 mg, Metformin 500 mg as Single Tablets
AUC0-tz for Linagliptin248 ± 14.5251 ± 15.3266 ± 22.1264 ± 23.8
Statistical analysis
  • Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet vs Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets · ANOVA · Adjusted gmean ratio: 99.5 · 90% CI 94.7 to 104.6
  • Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet vs Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets · ANOVA · Adjusted gmean ratio: 100.8 · 90% CI 95.1 to 106.8

Adverse events

Collected over First treatment with study drug until End-of-Study (which was 7 to 14 days after study drug treatment in Visit 3), i.e. 7 weeks plus 4 to 11 days after first treatment with study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet—0/23 (0%)0/23 (0%)
Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets—0/24 (0%)2/24 (8.3%)
Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet—0/24 (0%)0/24 (0%)
Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets—0/24 (0%)2/24 (8.3%)
Most frequent other events
Most frequent other events
EventLinagliptin 2.5 mg, Metformin 850 mg as FDC TabletLinagliptin 2.5 mg, Metformin 850 mg as Single TabletsLinagliptin 2.5 mg, Metformin 500 mg as FDC TabletLinagliptin 2.5 mg, Metformin 500 mg as Single Tablets
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/232/240/242/24

Baseline characteristics

Age Continuous
Age Continuous(years)Lina 2.5mg, Metformin 850mgLina 2.5mg, Metformin 500mgTotal
Mean27.8 ± 4.428.6 ± 4.828.2 ± 4.6
Sex: Female, Male
Sex: Female, Male(Participants)Lina 2.5mg, Metformin 850mgLina 2.5mg, Metformin 500mgTotal
Female121224
Male121224
08

Study locations

1 site
  • 1288.5.86001 Boehringer Ingelheim Investigational Site
    Beijing, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2012
First posted
Feb 28, 2012
Start
Feb 2012
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Aug 6, 2013
Last update
Aug 6, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01540487
Responsible party
Sponsor
First posted
Feb 28, 2012
Start date
Feb 2012
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Aug 6, 2013
Last update
Aug 6, 2013

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Linagliptin · Metformin

Start the discussion